Home Cart Sign in  
Chemical Structure| 915020-55-2 Chemical Structure| 915020-55-2

Structure of BGT226
CAS No.: 915020-55-2

Chemical Structure| 915020-55-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BGT226 is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BGT226 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, which may trigger the translocation of cytosolic Bax to the mitochondrial outer membrane, increasing mitochondrial membrane permeability; apoptotic cell death may ensue. Bax is a member of the proapoptotic Bcl2 family of proteins.

Synonyms: NVP-BGT226

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BGT226

CAS No. :915020-55-2
Formula : C28H25F3N6O2
M.W : 534.53
SMILES Code : O=C1N(C)C2=C(N1C3=CC(C(F)(F)F)=C(N4CCNCC4)C=C3)C5=CC(C6=CN=C(OC)C=C6)=CC=C5N=C2
Synonyms :
NVP-BGT226
MDL No. :MFCD22376639

Safety of BGT226

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of BGT226

PI3K-AKT

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice L. donovani infection model Oral 5 mg/kg Once daily for 5 days Evaluate the efficacy of NVP-BGT226 in VL mouse model PMC7221892

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00742105 Cancer|Solid Tumor|Advanced So... More >>lid Tumor Less << PHASE1 TERMINATED 2009-12-22 Novartis Investigative Site, N... More >>agoya, Aichi, 464-8681, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, 650-0017, Japan Less <<
NCT00600275 Solid Tumors|Breast Cancer|Cow... More >>den Syndrome Less << PHASE1|PHASE2 COMPLETED - Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana Faber Cancer Institute, Boston, Massachusetts, 02115, United States|Nevada Cancer Center, Las Vegas, Nevada, 89135, United States|Cancer Therapy and Research Center (CTRC), San Antonio, Texas, 78229, United States|Princess Margaret Hospital, Toronto, Canada|Novartis Investigative Site, Barcelona, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.94mL

18.71mL

3.74mL

1.87mL

 

Historical Records

Categories